Offstream
news

---

Changes

1. The Australian Technical Advisory Group on Immunisation gives Novavax the green light for Australia to approve the booster shot for their vaccine.
   2022-03-03 01:06:11 (First version)
2. The Australian Technical Advisory Group on Immunisation recommends the usage of the Novavax COVID-19 vaccine as a booster dose.
   (Current version)

---

Related

The Singaporean Health Sciences Authority grants interim authorisation for the use of the protein-based Novavax COVID-19 vaccine.
2022-02-14

The Standing Committee on Vaccination issues a recommendation for the approval of the protein-based Novavax COVID-19 vaccine for use in adults.
2022-02-3

The Australian Technical Advisory Group on Immunisation gives the final approval for use of the Novavax COVID-19 vaccine for people over the age of 18 years. The rollout of the vaccine will begin on February 21.
2022-01-24

The Ministry of Health and Family Welfare issues emergency use authorizations for the Covovax vaccine manufactured by the Serum Institute of India and the Corbevax vaccine. The ministry also issues an emergency use authorization for Merck & Co.'s anti-viral drug Molnupiravir.
2021-12-28

The European Commission authorizes the use of the Novavax COVID-19 vaccine after the European Medicines Agency recommended the use of the vaccine, becoming the fifth vaccine to be approved for use by the European Union.
2021-12-20

The Food and Drug Administration of the Philippines authorises emergency use of the Novavax COVID-19 vaccine, which will be included in the national vaccination program.
2021-11-17

Indonesia becomes the first country in the world to approve the protein-based Novavax COVID-19 vaccine, which will be manufactured by the Serum Institute of India.
2021-11-1

The Ministry of Health, Labour and Welfare signs a agreement with the Takeda Pharmaceutical Company to purchase 150 million doses of the Novavax COVID-19 vaccine that will be manufactured and distributed domestically by Takeda beginning next year.
2021-09-7

The Australian federal government restricts the usage of the Oxford–AstraZeneca vaccine to people over the age of 60 following a new recommendation from the Australian Technical Advisory Group on Immunisation.
2021-06-17

Phase III clinical trials for the Novavax COVID-19 vaccine candidate conclude in the U.S. and Mexico, showing an efficacy rating of 90.4%, down from the initial estimate of 96.4% efficacy reported in March. Additionally, the vaccine candidate was also found to be 86.3% effective against the Lineage B.1.1.7 Alpha variant that originated in the United Kingdom.
2021-06-14